[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630108":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":41,"collaborators":11,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":11,"eligibilityCriteria":48,"healthyVolunteers":45,"sex":49,"minAge":50,"maxAge":11,"enrollmentInfo":51,"targetDuration":11,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":11,"overallStatus":29,"whyStopped":11,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"The General Hospital of Western Theater Command","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Arm","EXPERIMENTAL",null,[13],"Drug: Lusutrombopag",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","Lusutrombopag","Lusutrombopag at a starting dose of 3 mg once daily. Treatment will continue for 2 weeks until CR is achieved, or treatment is discontinued after 14 days of continuous therapy, or when the discontinuation criteria are met. After the trial period plus 14 days, patients will be observed to determine if continued medication or regimen changes are necessary.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Lei Ma","CONTACT","+8615680600612","408955783@qq.com",[27],{"facility":28,"status":29,"city":30,"state":11,"zip":11,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"The General Hospital of the People's Liberation Army","RECRUITING","Chengdu","China","CN",{"type":34,"coordinates":35},"Point",[36,37],104.06667,30.66667,{"lat":37,"lon":36},[40],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},{"type":42,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100630108","efficacy-and-safety-of-lusutrombopag-after-allogeneic-hematopoietic-stem-cell-transplantation-100630108",false,"NCT07483385","Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\nParticipants must meet the following criteria:\n\n1. The patient signed an informed consent form and voluntarily participated in the study.\n2. Patients undergoing HLA haploidentical allogeneic hematopoietic stem cell transplantation;\n3. Age ≥18 years, regardless of gender\n4. ECOG score 0-2\n5. Expected survival ≥3 months\n6. No severe impairment of function of major organs\n\nExclusion Criteria:\n\nIf any of the following criteria are met, the participants must be excluded from this research project:\n\n1\\) Patients with known allergy to TPO-RAs; 2) Patients who cannot take oral medication due to gastrointestinal symptoms, altered mental status, etc. during transplantation; 3) Other reasons for exclusion as determined by the investigator.\n\n\\-","ALL","18 Years",{"count":52,"type":53},45,"ESTIMATED","INTERVENTIONAL",[56],"NA","This study is an investigator-initiated prospective, single-center, open-label clinical trial designed to evaluate the clinical efficacy and safety of Lusutrombopag in promoting platelet remodeling after allogeneic hematopoietic stem cell transplantation in patients with hematologic disorders.",[59,60],"Patients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation","Hematologic Disorders","2026-03-22",{"date":63,"type":64},"2026-03-25","ACTUAL",{"date":66,"type":64},"2026-01-13",{"date":68,"type":53},"2028-01-28",{"name":5,"class":6},1]